Rapid Micro Biosystem’s innovative Growth Direct System® platform is the only system to automate the compendial method of microbial quality control (QC) in the manufacture of healthcare products. The Growth Direct System fully automates traditional microbial testing – detects contamination more quickly, delivering compelling economic benefits, while improving quality control processes and data integrity.

The company completed its initial public offering in July, 2021, and is registered under the ticker Nasdaq:RPID.